ライフサイエンスコーパス: hydroxyethyl starch

1 is observed that matches the performance of hydroxyethyl starch.

2 preserved using 5% dimethyl sulfoxide and 6% hydroxyethyl starch.

3 ryopreserved in 5% dimethyl sulfoxide and 6% hydroxyethyl starch.

4 was reduced by lowering the concentration of hydroxyethyl starch.

5 nding properties of the 2 preparations of 6% hydroxyethyl starch.

6 < 0.001), 32.9+/-4.3 and 29.5+/-4.4mL/kg for hydroxyethyl starch 130/0.4 (p < 0.05), 31.8+/-3.9 and 2

7 ls: 1) hydroxyethyl starch (predominantly 6% hydroxyethyl starch 130/0.4) in 2004-2006, n = 2,137; 2)

8 s with hydroxyethyl starch (predominantly 6% hydroxyethyl starch 130/0.4) in the first period, 4% gel

9 roups and then hemodiluted by exchange of 6% hydroxyethyl starch (130,000:0.4) for whole blood to the

10 eive either 7.2% saline/6% hypertonic saline hydroxyethyl starch (4 mL/kg) or vehicle (NaCl 0.9 %) af

11 hich was not influenced by hypertonic saline hydroxyethyl starch administration.

12 Both low molecular weight hydroxyethyl starch and gelatin may impair renal functio

13 ater use of renal replacement therapy in the hydroxyethyl starch and gelatin periods compared to the

14 Hydroxyethyl starch and gelatin were independent risk fa

15 Resuscitation comprised hydroxyethyl starch and norepinenephrine infusion titrat

16 Resuscitation comprised of hydroxyethyl starch and norepinephrine infusion titrated

17 Resuscitation with hydroxyethyl starch and sham treatment significantly dec

18 data are available concerning the impact of hydroxyethyl starches and saline on pulmonary microperfu

19 each phase of critical illness, avoid use of hydroxyethyl starch, and facilitate fluid removal for pa

20 me expanders tested (e.g., dextran, gelatin, hydroxyethyl starch, and hypertonic saline).

21 d group (fluid ratios 1.4:1 [crystalloids to hydroxyethyl starch] and 1.1:1 [crystalloids to gelatin]

22 Clinical trials of hydroxyethyl starch are conflicting.

23 s are shown to be a suitable replacement for hydroxyethyl starch as a extracellular matrix for red bl

24 requiring acute volume resuscitation, use of hydroxyethyl starch compared with other resuscitation so

25 pha-lipoic acid as a diet supplement or with hydroxyethyl starch deferoxamine (HES-DFO) by weekly int

26 ypertonic solutions, it is hypothesized that hydroxyethyl starch enhances cerebral blood flow and imp

27 er models of brain injury, hypertonic saline hydroxyethyl starch failed to improve the outcome when a

28 Clinical use of hydroxyethyl starch for acute volume resuscitation is no

29 This might explain why hypertonic saline hydroxyethyl starch has failed to improve outcome in the

30 is study evaluated whether administration of hydroxyethyl starch (HES) 130/0.4 affects coagulation co

31 Hydroxyethyl starch (HES) [corrected] is widely used for

32 The safety and efficacy of hydroxyethyl starch (HES) for fluid resuscitation have n

33 of the carbohydrates trehalose, glucose, and hydroxyethyl starch (HES) on the motional properties of

34 known if use of colloid solutions containing hydroxyethyl starch (HES) to correct for intravascular d

35 on in the caudal vein of albumin, saline, or hydroxyethyl starch (HES).

36 ement of a volume equal to shed blood of 10% hydroxyethyl starch in 0.9% saline (group 3); or 3.0% sa

37 llowed immediately by resuscitation with 10% hydroxyethyl starch in 0.9% saline in a volume equal to

38 Hydroxyethyl starch is commonly used for volume resuscit

39 Hydroxyethyl starch is no longer recommended, and debate

40 effects of intravenous administration of 6% hydroxyethyl starch (maize-derived) in 0.9% saline (Volu

41 comparable at baseline in all study periods (hydroxyethyl starch n = 360, gelatin n = 352, only cryst

42 flow increases to hemodilution, and neither hydroxyethyl starch nor 3.0% hypertonic saline restored

43 hage and traumatic brain injury, neither 10% hydroxyethyl starch nor 3.0% hypertonic saline restored

44 renal replacement therapy was greater after hydroxyethyl starch (odds ratio, 2.29; 95% CI, 1.47-3.60

45 ocortex with no effects of hypertonic saline hydroxyethyl starch on neuronal survival.

46 Colloids (n = 1414; gelatins, dextrans, hydroxyethyl starches, or 4% or 20% of albumin) or cryst

47 ing the CPB pump with a low-molecular-weight hydroxyethyl starch pentastarch (PS) solution, PS conjug

48 Total fluid requirement was 163 mL/kg in the hydroxyethyl starch period, 207 mL/kg in the gelatin per

49 Kingdom) and a "balanced" preparation of 6% hydroxyethyl starch (potato-derived) [Plasma Volume Redi

50 ICU directed at preset hemodynamic goals: 1) hydroxyethyl starch (predominantly 6% hydroxyethyl starc

51 py directed at preset hemodynamic goals with hydroxyethyl starch (predominantly 6% hydroxyethyl starc

52 from SCT products was not possible by using hydroxyethyl starch sedimentation but was achievable wit

53 s 12.1 days; P < .001), and it reported that hydroxyethyl starch significantly increased the incidenc

54 f blood volume using a high-molecular-weight hydroxyethyl starch solution (Hextend, Hospira, MW 670 k

55 We included 38 eligible trials comparing hydroxyethyl starch to crystalloids, albumin, or gelatin

56 Hypertonic saline hydroxyethyl starch treatment resulted in an accentuated

57 r death among patients randomized to receive hydroxyethyl starch was 1.07 (95% CI, 1.00 to 1.14; I2,

58 retracted because of scientific misconduct, hydroxyethyl starch was associated with a significant in

59 d these 7 trials that involved 590 patients, hydroxyethyl starch was found to be associated with incr